Please ensure Javascript is enabled for purposes of website accessibility

Invitae Acquiring ArcherDX, Stock Skyrockets 45%

By Keith Speights – Jun 22, 2020 at 5:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The combination of the two companies will create a genetics powerhouse.

Invitae (NVTA -4.69%) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Under the terms of the deal, Invitae will provide $325 million in cash and 30 million shares of Invitae common stock upfront. In addition, another 27 million shares of Invitae common stock will be payable contingent upon the achievement of specified milestones. Invitae stock skyrocketed as much as 48.4% on the news before closing 45% higher. 

ArcherDX had planned to conduct an initial public offering (IPO) with the goal of raising up to $100 million. But those plans changed. ArcherDX CEO Jason Myer stated: "We are thrilled to unite with Invitae to form the leading hub for precision oncology, diagnostics, therapy optimization and monitoring, with an opportunity to accelerate both patient care and shareholder value."

Test tubes with DNA helixes

Image source: Getty Images.

Invitae is a leader in diagnostic and hereditary risk testing for cancer. ArcherDX provides gene-sequencing products and services used to determine the most effective cancer therapies and personalized cancer monitoring.

With the acquisition of ArcherDX, Invitae will be able to offer a single platform for cancer testing, including germline testing (on cells that don't have cancer), somatic testing (on cancerous cells), liquid biopsy, and tissue genomic profiling.

The boards of directors of both Invitae and ArcherDX have approved the deal. Shareholders of both companies must also vote in favor of the acquisition. Invitae expects the transaction to close within the next few months.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Invitae. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
$2.44 (-4.69%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.